Skip to content
Dr. Cannabis

Parkinson's disease

Movement disorder. NASEM found no or insufficient evidence.

Insufficient evidenceMixed findings, a single poor-quality study, or the question has not been studied.

What the evidence says

NASEM 2017: no or insufficient evidence for cannabis in Parkinson's disease.

NASEM placed Parkinson's disease in the no-or-insufficient-evidence category, alongside dystonia, Huntington's disease, and ALS.

Some people report subjective benefit for tremor or sleep. That is not the same as demonstrated efficacy, and orthostatic hypotension and falls are meaningful risks in this population.

What to ask for

This is a starting point, not a prescription. Take it to a licensed dispensary and ask to see the batch certificate of analysis.

Suggested ratio
CBD-forward if trying at all
Starting THC dose
None — CBD-led approach
Commonly chosen profile
CBD-dominant
Time of day
either

Cannabinoids

  • CBD

    Non-intoxicating. The only cannabis-derived compound with an FDA-approved medicine behind it, and the cannabinoid most often used to soften THC.

Terpenes to look for

Commonly present in products people choose for this. Terpene effect claims are preclinical — this is a way to find a product again, not a promise about how it will feel.

  • Linalool

    Floral, lavender, slightly spicy

Formats

  • TinctureOnset 15–90 min · lasts 4–8 h

    Liquid extract dosed by dropper. The most precise way to titrate an oral dose in small increments.

Get a personalised starting point

Answer four questions and we will adjust the dose for your experience level and find licensed dispensaries near you.

Get guidance

Talk to a doctor if

  • • Always involve your neurologist
  • • You have had falls or dizziness on standing

Related conditions

Sources

  1. NASEM 2017, Committee Conclusions (summary PDF of all evidence-tier conclusions).Accessed 2026-08-15.